Breaking News
February 22, 2019 - Oncotype DX Not Cost-Effective for Low-Risk Breast Cancer
February 22, 2019 - Scientists discover new type of immune cells that are essential for forming heart valves
February 22, 2019 - Talk About Déjà Vu: Senators Set To Re-Enact Drug Price Hearing Of 60 Years Ago
February 22, 2019 - Genetic defect linked to pediatric liver disease identified
February 22, 2019 - New cellular atlas could provide a deeper insight into blinding diseases
February 22, 2019 - Growing number of cancer survivors, fewer providers point to challenge in meeting care needs
February 22, 2019 - Innovative compound offers a new therapeutic approach to treat multiple sclerosis
February 22, 2019 - $1.5 million grant to develop opioid treatment program for jail detainees
February 22, 2019 - FDA’s new proposed rule would update regulatory requirements for sunscreen products in the U.S
February 22, 2019 - Most Hip, Knee Replacements Last Decades, Study Finds
February 22, 2019 - Wellness problems prevalent among ob-gyn residents
February 22, 2019 - In the Spotlight: “The world is your oyster in geriatrics”
February 22, 2019 - Successful testing of multi-organ “human-on-a-chip” could replace animals as test subjects
February 22, 2019 - Analysis of cervical precancer shows decline in two strains of HPV
February 22, 2019 - Sugary stent eases suturing of blood vessels
February 22, 2019 - From surgery to psychiatry: A medical student reevaluates his motivations
February 22, 2019 - Is New App From Feds Your Answer To Navigating Medicare Coverage? Yes And No
February 22, 2019 - New pacemakers powered by heartbeats could reduce need for surgery
February 22, 2019 - The United States records highest drug overdose death rates
February 22, 2019 - Phase 1 data reinforce safety profile of new drug for treating Duchenne muscular dystrophy
February 22, 2019 - Vitamin D supplementation less effective in the presence of obesity, shows study
February 22, 2019 - Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
February 22, 2019 - An institutional effort to reduce the amount of opioids prescribed following lumbar surgery
February 22, 2019 - Family-history-based models perform better than non-family-history based models
February 22, 2019 - Failure to take statins leads to higher mortality rates | News Center
February 22, 2019 - New study explains why some patients report phantom sensations after limb amputation
February 22, 2019 - First motor-controlled heart valves implanted by Mainz University Medical Center
February 22, 2019 - Novel preclinical model mimics persistent interneuron loss seen in preterm infants
February 22, 2019 - Global health burden of glaucoma has increased, study reveals
February 22, 2019 - A holistic approach key to minimize treatment complexity in patients with interstitial lung disease
February 22, 2019 - 1 in 10 middle-aged Chinese adults are at high risk for heart disease, finds study
February 22, 2019 - More than half a million breast cancer patient’s lives saved by improvements in treatment
February 22, 2019 - Study finds no evidence that tougher policies prevent teenage cannabis use
February 22, 2019 - New blood test detects genetic disorders in fetuses
February 22, 2019 - Lower Self-Perception Observed in Children With Amblyopia
February 22, 2019 - Up to 15 percent of children have sleep apnea, yet 90 percent go undiagnosed
February 22, 2019 - Rare pulmonary defect prompts parents’ nationwide search for answers | News Center
February 22, 2019 - Lesbian and bisexual women at greater risk of being overweight, study finds
February 22, 2019 - UQ research may explain why vitamin D is essential for brain health
February 22, 2019 - Heart Attacks Rising Among Younger Women
February 22, 2019 - How your smartphone is affecting your relationship
February 22, 2019 - Orthopaedic surgeon receives prestigious award, $10 million grant | News Center
February 22, 2019 - New sepsis test could save thousands of lives
February 22, 2019 - Cervical cancer could be eradicated by 2100
February 21, 2019 - Sustained smoking cessation can lower risk of seropositive RA
February 21, 2019 - Thousands with chronic UTIs are not receiving the treatment they need
February 21, 2019 - Are teens getting high on social media? The surprising study seeking the pot-Instagram link
February 21, 2019 - Stanford expands biobank services | News Center
February 21, 2019 - Scientists identify link between drinking contexts and early onset intoxication among adolescents
February 21, 2019 - Strong social support may reduce cardiovascular disease risk in postmenopausal women
February 21, 2019 - Rapid expansion of interventions could prevent up to 13 million cases of cervical cancer within 50 years
February 21, 2019 - Motif Bio Receives Complete Response Letter From The FDA
February 21, 2019 - Researchers map previously unknown disease in children
February 21, 2019 - A skeptical look at popular diets: Going gluten-free
February 21, 2019 - Podcast: KHN’s ‘What The Health?’ How Safe Are Your Supplements?
February 21, 2019 - Factors associated with increased risk of developing surgical site infections
February 21, 2019 - Anticipatory signals in eye movements can help measure attentive capacity, learning with greater precision
February 21, 2019 - Study explores daily exposure to indoor air pollutants
February 21, 2019 - Evening exercise does not negatively affect sleep, may also reduce hunger
February 21, 2019 - Artificial intelligence technique can be used to identify alcohol misuse in trauma setting
February 21, 2019 - Overweight, obesity in adolescence associated with increased risk of renal cancer later in life
February 21, 2019 - BGU develops new AI platform for monitoring and predicting ALS progression
February 21, 2019 - Researchers discover a new promising target to improve HIV vaccines
February 21, 2019 - Brief Anesthesia in Infancy Does Not Mar Neurodevelopment
February 21, 2019 - Gaming system helps with autism diagnosis
February 21, 2019 - Heart Disease: Six Things Women Should Know
February 21, 2019 - More States Say Doctors Must Offer Overdose Reversal Drug Along With Opioids
February 21, 2019 - Researchers explore case studies focused on industries that kill more people than employed
February 21, 2019 - Only half of GP practice buildings are fit for purpose
February 21, 2019 - Intense exercise, fasting and hormones can enhance waste-protein removal, study shows
February 21, 2019 - Scientists can monitor brain activity to predict epileptic seizures few minutes in advance
February 21, 2019 - Study quantifies hepatic and intestinal mRNA expression of Ugt isoforms in rats
February 21, 2019 - ‘Apple-Shaped’ Body? ‘Pear-Shaped’? Your Genes May Tell
February 21, 2019 - Can we repair the brain? The promise of stem cell technologies for treating Parkinson’s disease
February 21, 2019 - Trump Plan To Beat HIV Hits Rough Road In Rural America
February 21, 2019 - PENTAX Medical introduces new electrosurgical and argon plasma coagulation platforms
February 21, 2019 - Trump plan to beat HIV hits rough road in rural America
February 21, 2019 - Eating blueberries every day could help decrease blood pressure
February 21, 2019 - ‘No Second Chances’ report calls for new measures to combat cardiovascular disease in Australia
February 21, 2019 - Mayo clinic researchers discuss local case studies of leprosy
Research highlights ability of Bio-Rad’s ddPCR in quantifying minimal residual disease

Research highlights ability of Bio-Rad’s ddPCR in quantifying minimal residual disease

image_pdfDownload PDFimage_print

More than 30 abstracts presented at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego, December 1-4, featured research highlighting the ability of Bio-Rad’s Droplet Digital PCR (ddPCR) to provide high sensitivity and accuracy in quantifying minimal residual disease (MRD) — those remaining cancer cells after therapy that are associated with relapse — in blood diseases such as leukemia.

One study described how ddPCR may be able to more accurately determine MRD than qPCR and therefore better determine which patients with childhood acute lymphoblastic leukemia are eligible for high-risk treatments. In another study, researchers found that the concentration of residual leukemic cells, determined by the QX200 Droplet Digital PCR System, was one of the risk factors that predicted relapse in patients with chronic myeloid leukemia who had discontinued therapy. In addition to these studies, below are highlights of other presentations that showed how ddPCR is used to measure MRD in patients with acute myeloid leukemia (AML).

ddPCR utilization in phase 1b trial in TP53-mutant MDS and AML

The following poster (abstract number 3091) was presented on Sunday, December 2.

Dr. David Sallman, a hematologic oncologist at the Moffitt Cancer Center in Tampa, Florida, presented results from a phase 1b clinical trial enabled by ddPCR. Dr. Sallman and his team tested the use of azacitidine, a chemotherapy drug, in combination with small-molecule drug APR-246 in patients with myelodysplastic syndromes (MDS) and AML with TP53 mutations. Data have previously shown that azacitidine alone leads to complete remission in 20 to 30% of patients with TP53 mutant MDS and AML. The results of this study showed that 82% of these patients achieved complete remission when APR-246 was added, representing a significant improvement over treatment with azacitidine alone.

The researchers used next-generation sequencing (NGS) and ddPCR to analyze the depth of remission by quantifying MRD. “In our trial we found that ddPCR was extremely effective at defining patient-specific depth of remission,” Dr. Sallman said.

Phase 2 of the trial will continue to use ddPCR as one of the ways to determine the depth of remission, noted Dr. Sallman, adding that remission, as defined by ddPCR and high-sensitivity NGS assays, would also be evaluated as a predictor of outcomes in patients treated with APR-246 and azacitidine.

ddPCR helps predict remission in patients with AML

The following poster (abstract number 2139) was presented on Saturday, December 1.

Allogenic hematopoietic stem cell transplantation (HSCT) is one of the only curative therapies for hematologic malignancies such as AML. However, many patients relapse after transplantation.

Dr. Amanda Winters, MD, PhD, of the Department of Pediatrics at the University of Colorado and Children’s Hospital Colorado, and her team evaluated the use of ddPCR for monitoring MRD to predict which patients might relapse after HSCT. While MRD has previously been shown to be highly predictive of relapse for patients after chemotherapy, few studies have evaluated its predictive ability in HSCT.

The team used single-mutation ddPCR assays to track 21 different AML-associated mutations in a 36-patient cohort. All patients selected for this retrospective study had received a bone marrow transplant and consented to the Tissue Bank protocol, making past marrow and peripheral blood samples available to researchers. The patients had also been identified as having at least one of the 21 mutations at diagnosis.

The research found that ddPCR-based molecular MRD assessment was predictive for relapse and survival post-HSCT for patients with AML. The presence of molecular MRD at the one-month point after transplant was significantly correlated with relapse and mortality. Based on these findings, Dr. Winters and her team believe monitoring AML-associated mutations with ddPCR after transplant could help physicians detect relapse earlier.​

Tagged with:

About author

Related Articles